Back to Results
First PageMeta Content
Medical statistics / Design of experiments / Evaluation methods / Ruxolitinib / Essential thrombocytosis / Polycythemia vera / Myelofibrosis / Thrombocytosis / Clinical trial / Medicine / Pharmacology / Clinical research


Document Date: 2014-10-01 21:56:24

Open Document

File Size: 83,58 KB

Share Result on Facebook

Company

Novartis Pharmaceuticals Australia Pty Ltd / /

Country

Australia / /

Currency

USD / /

Facility

Consumer Comments facility / /

IndustryTerm

proposed treatment algorithm / Cancer Therapy / Treatment of Cancer / assumed utilities / /

MedicalCondition

post-essential thrombocythemia myelofibrosis / polycythemia vera / Cancer Therapy Lymphoma / disease / post-polycythemia vera myelofibrosis / essential thrombocythemia / acute myeloid leukaemia / rare disease / postpolycythemia vera myelofibrosis / thrombocytopenia / primary myelofibrosis / polycythemia vera myelofibrosis / severe lethargy / pain / myeloproliferative neoplasm / Proposed Therapy Myelofibrosis / essential thrombocythemia myelofibrosis / low risk disease / myelofibrosis / fibrosis / /

MedicalTreatment

blood transfusions / Cancer Therapy / /

Organization

European Organisation for Research and Treatment of Cancer / Australian Committee on Prescription Medicines / Listing Requested and PBAC’s View Authority / /

Position

driver / Trial ID/ First author / /

Product

hydroxyurea / Ruxolitinib / /

Technology

author Protocol / treating cancer / transplantation / stem cells / proposed treatment algorithm / MRI / /

SocialTag